Abstracts tagged "anti-TNF therapy"

Abstract Number: 1413 • 2013 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy Of Certolizumab Pegol In Combination With Methotrexate In The Treatment Of Rheumatoid Arthritis: 5-Year Results From a 52-Week Randomized Controlled Trial and Open-Label Extension Study
Edward Keystone¹, Robert Landewé², Ronald van Vollenhoven³, Bernard Combe⁴, Vibeke Strand⁵, Philip J. Mease⁶, Laura Shaughnessy⁷, Brenda VanLunen⁷ and Désirée van der Heijde⁸, ¹University of Toronto, Toronto, ON, Canada, ²Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands, ³Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ⁴Montpellier University Hospital, Montpellier, France, ⁵Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ⁶Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ⁷UCB Pharma, Raleigh, NC, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: In the RAPID1 randomized controlled trial (RCT; NCT00152386),1 certolizumab pegol (CZP) every 2 weeks (Q2W) plus MTX over 52 weeks (wks) provided rapid improvements…
Abstract Number: 349 • 2013 ACR/ARHP Annual Meeting
Serum CTX-I Predicts Systemic Bone Loss At The Hip Over 1 Year In Patients With Early Psoriatic Arthritis
Agnes Szentpetery¹, Mark Kilbane², Myra P. O'Keane², Muhammad Haroon³, Phil Gallagher⁴, Susan van der Kamp⁵, Malachi McMenna⁶ and Oliver FitzGerald³, ¹Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ²Metabolism Laboratory, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ³Department of Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ⁴Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ⁵DXA Unit, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ⁶Department of Endocrinology & Metabolic Bone Disease, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: There is a growing interest in bone and cartilage biomarkers that could be used predicting and assessing changes in structural damage in inflammatory arthritis.…
Abstract Number: 2483 • 2013 ACR/ARHP Annual Meeting
Periarticular Bone Gain In Early Psoriatic Arthritis But Not In Rheumatoid Arthritis Following Anti-Rheumatic Treatment As Measured By Digital X-Ray Radiogrammetry
Agnes Szentpetery¹, Muhammad Haroon², Phil Gallagher³, Eric J. Heffernan⁴ and Oliver FitzGerald², ¹Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ²Department of Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ³Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ⁴Radiology, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Hand bone loss is an early feature in both RA and PsA, but there is less data available on periarticular bone gain, in particular…
Abstract Number: 1799 • 2013 ACR/ARHP Annual Meeting
Effect Of Certolizumab Pegol Over 48 Weeks In Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Robert B. M. Landewé¹, Martin Rudwaleit², Désirée M. van der Heijde³, Maxime Dougados⁴, Philip Mease⁵, John D. Reveille⁶, Jessica Walsh⁷, Alan J. Kivitz⁸, Walter P. Maksymowych⁹, Jürgen Braun¹⁰, Atul A. Deodhar¹¹, Christian Stach¹², Bengt Hoepken¹², Pritibha Singh¹² and Joachim Sieper¹³, ¹Academic Medical Center/University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, ²Endokrinologikum Berlin, Berlin, Germany, ³Dept of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ⁵Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA, ⁶Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁷Rheumatology, University of Utah Hospital, Salt Lake City, UT, ⁸Altoona Center for Clinical Research, Duncansville, PA, ⁹Medicine, University of Alberta, Edmonton, AB, Canada, ¹⁰Rheumazentrum Ruhrgebiet, Herne, Germany, ¹¹Div of Arthritis & Rheum OP-09, Oregon Health & Science University, Portland, OR, ¹²UCB Pharma, Monheim, Germany, ¹³Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany
Background/Purpose: Previous reports of RAPID-axSpA have demonstrated the efficacy and safety of certolizumab pegol (CZP), a PEGylated Fc-free anti-TNF, in patients (pts) with axial spondyloarthritis…
Abstract Number: 1363 • 2013 ACR/ARHP Annual Meeting
Active Tuberculosis Risk With Tumor Necrosis Factor Inhibitors After Treating Latent Tuberculosis -a 7-Year Retrospective Observational Study
Minkyung Kwon¹, Mindong Sung¹, Yong-Jin Kwon¹, Young Goo Song¹, Sang-Won Lee², Min-Chan Park¹, Yong-Beom Park¹, Soo-Kon Lee¹ and Jason Jungsik Song¹, ¹Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ²Department of Internal Medicine, Yonsei University College of Medicine, Seoul, NV, South Korea
Background/Purpose: Active tuberculosis (TB) risk increases during anti-tumor necrosis factor (TNF) therapy and latent TB infection (LTBI) screening is recommended in potential TNF inhibitor users.…
Abstract Number: 326 • 2013 ACR/ARHP Annual Meeting
Reduction Of Disease Burden On Workplace and Household Productivity In Psoriatic Arthritis Over 48 Weeks Of Treatment With Certolizumab Pegol
Arthur Kavanaugh¹, Dafna D. Gladman², Désirée M. van der Heijde³, Oana Purcaru⁴ and Philip J. Mease⁵, ¹Division of Rheumatology Allergy and Immunology, University of California San Diego, San Diego, CA, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴UCB Pharma, Brussels, Belgium, ⁵Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: Compared to the general population, patients (pts) with psoriatic arthritis (PsA) suffer greater amounts of disability and substantially lower employment rates.1 To date there…
Abstract Number: 2486 • 2013 ACR/ARHP Annual Meeting
Clinical Performance Of 4 Methods For Detecting Latent Tuberculosis Infection (LTbI) In Patients With Active Chronic Inflammatory Arthritis Taking TNFα Blockers
Carina M F Gomes¹, Maria Teresa Terreri², Maria Isabel Pinto³, Karen Oseki³, Fernanda Spina⁴ and Marcelo M. Pinheiro⁵, ¹Rheumatology Division, Universidade Federal de São Paulo, Sao Paulo, Brazil, ²Pediatrics, Universidade Federal de São Paulo / UNIFESP, Sao Paulo, Brazil, ³Pediatrics, Universidade Federal de São Paulo, Sao Paulo, Brazil, ⁴Rheumatology Division, Universidade Federal de São Paulo Unifesp/EPM, Brazil, Universidade Federal de São Paulo, Sao Paulo, Brazil, ⁵Brazilian Registry of Spondyloarthritis, São Paulo, Brazil
Background/Purpose: About 5% of the Brazilian population has some chronic inflammatory arthropathy (CIA), including rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PA) and juvenile…
Abstract Number: 1697 • 2013 ACR/ARHP Annual Meeting
Are Patients With Rheumatoid Arthritis Still At An Increased Risk Of Tuberculosis and What Is The Role Of Biological Treatment?
Elizabeth V. Arkema¹, Jerker Jonsson², Eva Baecklund³, Maud Rutting⁴, Judith Bruchfeld⁵, Nils Feltelius⁴ and Johan Askling^1,6, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Swedish Institute for Communicable Disease Control, Solna, Sweden, ³Department of Medical Sciences, Rheumatology, Uppsala University Hospital, Uppsala, Sweden, ⁴Swedish Medical Products Agency, Uppsala, Sweden, ⁵Department of Medicine, Infectious Diseases Unit, Karolinska Institutet, Stockholm, Sweden, ⁶Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Anti-TNF therapy is a risk factor for clinical tuberculosis (TB), which has led to pre-treatment screening and increased vigilance. The extent to which…
Abstract Number: 1367 • 2013 ACR/ARHP Annual Meeting
Performance Of a Two-Step Latent Tuberculosis Screening Algorithm In Patients With Rheumatoid Arthritis, Psoriatic Arthritis Or Ankylosing Spondylitis Prior To Treatment With Tumor Necrosis Alpha Inhibitors: Prospective Observational Data From The Biorx.Si Registry
ŽIga Rotar¹ and Matija Tomsic², ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Department of Rheumatology, University Medical Centre Ljubjana, Ljubljana, Slovenia
Background/Purpose: Reactivation of latent tuberculosis infection (LTBI) is of concern in patients treated with TNFi. Conversely, TB chemoprophylaxis (CP) is time consuming, delays the initiation…
Abstract Number: 313 • 2013 ACR/ARHP Annual Meeting
The DC-STAMP⁺IL17A⁺ Cell Subset Is Elevated In Psoriatic Arthritis (PsA) Patients and Declines Following Anti-TNFi Therapy
Yahui Grace Chiu¹, Edward M. Schwarz², Hua He³, Francisco A. Tausk⁴, Sharon Moorehead⁵, Michelle Smith⁵ and Christopher T. Ritchlin⁵, ¹Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, ²Center for Musculoskeletal Research, University of Rochester, Rochester, NY, ³Biostatistics and Computational Biology, University of Rochester, Rochester, NY, ⁴Dermatology, University of Rochester, Rochester, NY, ⁵Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY
Background/Purpose: Approximately 25% of psoriasis (Ps) patients develop psoriatic arthritis (PsA), a potentially destructive joint disease, within 10 years of Ps onset. Although early diagnosis…
Abstract Number: 2455 • 2013 ACR/ARHP Annual Meeting
The Lipid Profile Improves In Patients With Ankylosing Spondylitis Responding To TNF Blocking Therapy
Sjoerd C. Heslinga^1,2, Irene E. Van der Horst-Bruinsma^3,4, Alper M. van Sijl^2,3 and Michael T Nurmohamed^1,5, ¹Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ³Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁴Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁵VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Patients with ankylosing spondylitis (AS) have a decreased life expectancy due to an increased cardiovascular risk. Cardiovascular risk factors such as smoking, dyslipidemia, overweight,…
Abstract Number: 1548 • 2013 ACR/ARHP Annual Meeting
Effect Of TNF Inhibitors On Bone Mineral Density In Patients With Ankylosing Spondylitis- a Systematic Review and Meta-Analysis
Nisha Nigil Haroon¹, Jeevitha Srighanthan², Nayef AL Ghanim³, Robert D. Inman^4,5,6,7,8,9 and Angela Cheung¹⁰, ¹Medicine, University of Toronto, Toronto, ON, Canada, ²Osteoporosis Program, University of Toronto, Ontario, ON, Canada, ³Rheumatology, University of Toronto, Toronto, ON, Canada, ⁴Toronto Western Hospital, Toronto, ON, Canada, ⁵Rheumatology, Toronto Western Research Institute. University of Toronto, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Dept of Medicine/Rheumatology, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ⁸U of Toronto, Toronto, ON, Canada, ⁹Dept of Medicine/Rheumatology, The Arthritis Program, Toronto Western Hospital and Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ¹⁰Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with ankylosing spondylitis (AS) are susceptible to osteoporosis (OP) and have high fracture risk. Currently, no specific strategies are established to treat OP…
Abstract Number: 1351 • 2013 ACR/ARHP Annual Meeting
A Comparison Of The Clinical Effectiveness Of Treatment Strategies For Active RA Patients : Using a Prospective Biologic Registry (BIOPSY) and an RA Specific Cohort (KORONA)
Yoon-Kyoung Sung^1,2, Soo-Kyung Cho^1,2, Chan-Bum Choi^3,4, Soyoung Won⁵, So-Young Bang⁶, Hoon-Suk Cha⁷, Jung-Yoon Choe⁸, Won Tae Chung⁹, Seung-Jae Hong¹⁰, Jae-Bum Jun⁴, Hyoun Ah Kim¹¹, Jinseok Kim¹², Seong-Kyu Kim⁸, Tae-Hwan Kim⁴, Hye-Soon Lee¹³, Jaejoon Lee⁷, Jisoo Lee¹⁴, Shin-Seok Lee¹⁵, Sung Won Lee¹⁶, Yeon-Ah Lee¹⁰, Seong-Su Nah¹⁷, Chang-Hee Suh¹⁸, Dae-Hyun Yoo⁴, Bo Young Yoon¹⁹ and Sang-Cheol Bae^1,2, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Department of Rheumatology, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ³Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁴Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁵Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁶Hanyang University Guri Hospital, Guri, South Korea, ⁷Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁸Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁹Division of Rheumatology, Department of Internal Medicine, Dong-A University Hospital, Busan, South Korea, ¹⁰Division of Rheumatology, Department of Internal Medicine, Kyung Hee University, Seoul, South Korea, ¹¹Ajou University Hospital, Suwon, South Korea, ¹²Division of Rheumatology, Internal Medicine, Jeju National University Hospital, Jeju, Korea, South Korea, ¹³Department of Rheumatology, Hanyang University Guri Hospital, Guri, South Korea, ¹⁴Internal Medicine, Ewha Womans University Mokdong Hospital, Seoul, South Korea, ¹⁵Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea, ¹⁶Rheumatology, Dong-A University Hospital, Busan, South Korea, ¹⁷Division of Rheumatology, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, South Korea, ¹⁸Department of Rheumatology, Ajou University Hospital, Suwon, South Korea, ¹⁹Inje University Ilsan Paik Hospital, Goyang, South Korea
Background/Purpose: The results from RCTs may not be generalizable to clinical practice because of their inclusion and exclusion criteria. Instead, observational cohorts and registries might…
Abstract Number: 283 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Biologic Treatments In Juvenile Idiopathic Arthritis With a Polyarticular Course: An Indirect Comparison
Laura Sawyer¹, Alex Diamantopoulos², Hermine Brunner³, Fabrizio De Benedetti⁴, Nicolino Ruperto⁵, Fred Dejonckheere⁶ and Caroline Keane⁷, ¹Symmetron Limited, London, United Kingdom, ²Symmetron Limited, Herts, United Kingdom, ³PRCSG, Cincinnati, OH, ⁴Division of Rheumatology, Department of Pediatric Medicine, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ⁵PRINTO, Genoa, Italy, ⁶F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁷Roche, Welwyn Garden City, United Kingdom
Background/Purpose: To date there are no head-to-head trials comparing the efficacy of biologic treatments for polyarticular-course JIA (pcJIA). The purpose of this study was to…
Abstract Number: 2431 • 2013 ACR/ARHP Annual Meeting
Association Of T Follicular Helper / Th17 T Cell and Memory B Cell Populations In Rheumatoid Arthritis With Disease Activity and Therapy With TNF Antagonists
Marc C. Levesque¹, Camilla Macedo², Lisa Boyette², Kevin Hadi³, Erich R Wilkerson⁴, Diana Metes², Larry W. Moreland⁵ and Mandy J. McGeachy⁶, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³Univeristy of Pittsburgh, Pittsburgh, PA, ⁴Medicine, University of Pittsburgh, Pittsburgh, PA, ⁵Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁶Medicine, Division of Rheumatology and Clinical Immunology, Univeristy of Pittsburgh, Pittsburgh, PA
Background/Purpose: Autoreactive memory B cells and T cells contribute to the pathogenesis of rheumatoid arthritis (RA) through production of antibodies and cytokines that activate monocytes…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].